How will the CEO and CSO earn their performance-based equity awards?

The PSUs are earned based on Regeneron's cumulative Total Shareholder Return (TSR) over a five-year period, starting from an initial share price of $478.30. A target payout of 100% is achieved with 65.6% absolute TSR (10.6% CAGR), while a maximum payout of 250% is earned upon achieving 140.4% absolute TSR (19.2% CAGR).

What is the total value and duration of these new equity awards?

The aggregate grant date fair value for accounting purposes for each executive's award is approximately $130 million, totaling $260 million for both. These awards are designed to cover compensation for the next five years, with earned PSUs subject to an additional three-year mandatory holding period, extending the alignment with shareholders for up to eight years.

Are there any conditions or restrictions on these PSUs?

Yes, the PSUs are 100% performance-based and are subject to stringent TSR goals. Furthermore, earned PSUs must be held for three years after vesting. The executives have agreed not to receive any further equity awards until December 2025. Termination clauses and a clawback policy also apply.

REGN 8-K: Leadership Changes

Q: What is the main change in executive compensation for Regeneron's CEO and CSO?

Effective December 31, 2020, Regeneron's CEO and CSO received a special, front-loaded five-year performance-based equity award consisting entirely of Performance Restricted Stock Units (PSUs). This replaces their usual annual equity awards for the next five years and eliminates time-based stock options from their compensation.

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced a significant shift in executive compensation for its CEO, Leonard S. Schleifer, M.D., Ph.D., and CSO, George D. Yancopoulos, M.D., Ph.D., effective December 31, 2020. In lieu of traditional annual equity awards for the next five years, both executives received a special, front-loaded performance-based equity award consisting entirely of Performance Restricted Stock Units (PSUs). This move is intended to further align executive interests with long-term shareholder value creation and reflects a strategic decision to eliminate time-based stock options from their compensation. The PSUs are tied to achieving specific Total Shareholder Return (TSR) goals over a five-year performance period, with a target of 100% payout at a 65.6% absolute TSR (10.6% CAGR) and a maximum payout of 250% at a 140.4% absolute TSR (19.2% CAGR). Following vesting, there is a mandatory three-year holding period, reinforcing long-term commitment. The aggregate grant date fair value for accounting purposes for these awards is approximately $130 million for each executive, totaling $260 million. This compensation structure emphasizes performance and aims for leadership stability to support Regeneron's future growth.

Key Highlights

1Special, five-year performance-based equity award granted to CEO and CSO in lieu of annual awards.
2Compensation shifted entirely to Performance Restricted Stock Units (PSUs), eliminating time-based stock options.
3Awards are 100% performance-based, directly linking executive compensation to Total Shareholder Return (TSR) over five years.
4Target payout requires 65.6% absolute TSR (10.6% CAGR) over five years; maximum payout at 140.4% absolute TSR (19.2% CAGR).
5Each executive received awards with an aggregate grant date fair value of approximately $130 million.
6Earned PSUs are subject to a mandatory three-year holding period after vesting, promoting long-term alignment.
7Executives will not receive additional equity awards until the regular year-end grant cycle in December 2025.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jan 5, 2021)

Summary

Key Highlights

Frequently Asked Questions